OpenAI acquires startup Orchestra Bio to beef up its biotech business

What happened

OpenAI announced the acquisition of Orchestra Bio, a startup building AI agents for operational drug development coordination. Deal terms were not disclosed. Orchestra had raised ~$20 million from Andreessen Horowitz, Atria, and 8VC.

Context and impact

Orchestra joins the Rosalind Workbench — OpenAI's life sciences platform with customers including Moderna and Novo Nordisk. The acquisition follows GPT-Rosalind (April 2026) and investments in Chai Discovery, showing OpenAI systematically building a biomedical position.

Details

• Orchestra Bio: 4 years old, fewer than 10 employees
• Handled financial tracking and clinical trial scheduling for biotech
• Goal: strengthen Rosalind Workbench for experiment planning and results analysis
• Rosalind customers include Moderna and Novo Nordisk
• Financial terms not disclosed